Gastric cancer is the fourth most common cancer in the world and the second cancer cause. China has a high incidence of gastric cancer, accounting for 47% of the global total. System chemotherapy is the main treatment of advanced gastric cancer. After failure of first-line therapy, single agent of irinotecan is used as second line treatment in locally advanced or metastatic gastric or gastroesophageal junctional adenocarcinoma. The purpose of this study is to evaluate it there will be more benefit with irinotecan plus apatinib.